menu

Managing COVID-19 Related Delays In Patients with Neovascular AMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Managing COVID-19 Related Delays In Patients with Neovascular AMD

close
1.00 credits
1 Hour
Managing COVID-19 Related Delays In Patients with Neovascular AMD
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    The purpose of the virtual roundtable is to provide comprehensive education on the management of patients with neovascular AMD who experience delays in treatment as a result of the COVID-19 pandemic.  This will be achieved through in-depth examination of clinical trial data assessing the durability of response and maintenance of visual outcomes.

  • Provider

    This activity is jointly provided by Global Education Group and iVista Medical Education, Inc.

  • Commercial Support

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Target Audience

    The educational design of this activity addresses the needs of practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons, comprehensive ophthalmologists, and ophthalmic techs involved in the treatment of patients with neovascular AMD.

  • Educational Objectives

    After completing this activity, the participant should be better able to:

    • Describe how to manage treatment interruptions of patients with neovascular AMD resulting from COVID-19
    • Explain how to apply anti-VEGF durability data from randomized clinical trials to treatment decisions
    • Review anti-VEGF safety information as it relates to monitoring their patients
    • Evaluate future therapies based on their ability to improve durability and maintain visual outcomes in patients with neovascular AMD
  • Physician Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and iVista Medical Education, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians.

  • Physician Credit Designation

    Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Global Contact Information

    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

  • Instructions to Receive Credit

    In order to receive credit for this activity, the participant must attend read the CME information, watch the webcast video, score 70% or better on the posttest, and complete the program evaluation.

  • Fee Information& Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Term of Offering

    This activity was released on October 21, 2020 and is valid for one year. Requests for credit must be made no later than October 21, 2021.

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Sophie J. Bakri, MD

    Consultant/Independent Contractor: Adverum, Alimera, Allergan, EyePoint, Kala, Genentech, Inc, Novartis, Roche, Zeiss

    Dilsher S. Dhoot, MD

    Consultant/Independent Contractor: Genentech, Regeneron, Novartis, Alimera Sciences, Allergan, Ocular Therapeutix, Santen, Bayer, Allegro
    Grant/Research Support: Regeneron
    Honoraria: Genentech, Regeneron, Novartis, Alimera Sciences, Allergan, Ocular Therapeutix, Santen, Bayer, Allegro
    Speaker's Bureau: Genentech, Regeneron, Novartis, Alimera Sciences
    Advisory Board: Genentech, Regeneron, Novartis, Alimera Sciences, Allergan, Ocular Therapeutix, Santen, Bayer, Allegro
    Stock Shareholder: Vortex Surgical

     David A. Eichenbaum, MD

    Consultant/Independent Contractor: Genentech, Regeneron, Allergan, Clearside, Alimera, Notal Vision, EyePoint, Gyroscope, RecensMedical, Dutch Opthalmic
    Grant/Research Support: Genentech, Regeneron, Allergan, Clearside, Alimera, Ophthotech, Ophthea, Mylan, Chengdu, Gyroscope, Kodiak, NGM, Alkahest
    Honoraria: Genentech, Regeneron, Allergan, Clearside, Alimera, Notal Vision, EyePoint, Gyroscope, RecensMedical, Dutch Opthalmic
    Speaker's Bureau: Genentech, Allergan, Novartis, EyePoint, Dutch Ophthalmic
    Advisory Board: Genentech, Allergan, Novartis, Kodiak, EyePoint, Adverum
    Stock Shareholder: US Retina, Hemera Biosciences, Network Eye, Clearside

     Rishi P. Singh, MD

    Consultant/Independent Contractor: Regeneron, Alcon, Novartis, Genentech, Bausch and Lomb, Apellis
    Grant/Research Support: Aerie, Graybug, Apellis

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Yaremi Koopot, and Alana Ochoa all have reported that they do not have any relevant financial relationships to disclose.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and iVista Medical Education, Inc. do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The purpose of the virtual roundtable is to provide comprehensive education on the management of patients with neovascular AMD who experience delays in treatment as a result of the COVID-19 pandemic.  This will be achieved through in-depth examination of clinical trial data assessing the durability of response and maintenance of visual outcomes.

  • Provider

    This activity is jointly provided by Global Education Group and iVista Medical Education, Inc.

  • Commercial Support

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Target Audience

    The educational design of this activity addresses the needs of practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons, comprehensive ophthalmologists, and ophthalmic techs involved in the treatment of patients with neovascular AMD.

  • Educational Objectives

    After completing this activity, the participant should be better able to:

    • Describe how to manage treatment interruptions of patients with neovascular AMD resulting from COVID-19
    • Explain how to apply anti-VEGF durability data from randomized clinical trials to treatment decisions
    • Review anti-VEGF safety information as it relates to monitoring their patients
    • Evaluate future therapies based on their ability to improve durability and maintain visual outcomes in patients with neovascular AMD
  • Physician Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and iVista Medical Education, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians.

  • Physician Credit Designation

    Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Global Contact Information

    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

  • Instructions to Receive Credit

    In order to receive credit for this activity, the participant must attend read the CME information, watch the webcast video, score 70% or better on the posttest, and complete the program evaluation.

  • Fee Information& Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Term of Offering

    This activity was released on October 21, 2020 and is valid for one year. Requests for credit must be made no later than October 21, 2021.

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Sophie J. Bakri, MD

    Consultant/Independent Contractor: Adverum, Alimera, Allergan, EyePoint, Kala, Genentech, Inc, Novartis, Roche, Zeiss

    Dilsher S. Dhoot, MD

    Consultant/Independent Contractor: Genentech, Regeneron, Novartis, Alimera Sciences, Allergan, Ocular Therapeutix, Santen, Bayer, Allegro
    Grant/Research Support: Regeneron
    Honoraria: Genentech, Regeneron, Novartis, Alimera Sciences, Allergan, Ocular Therapeutix, Santen, Bayer, Allegro
    Speaker's Bureau: Genentech, Regeneron, Novartis, Alimera Sciences
    Advisory Board: Genentech, Regeneron, Novartis, Alimera Sciences, Allergan, Ocular Therapeutix, Santen, Bayer, Allegro
    Stock Shareholder: Vortex Surgical

     David A. Eichenbaum, MD

    Consultant/Independent Contractor: Genentech, Regeneron, Allergan, Clearside, Alimera, Notal Vision, EyePoint, Gyroscope, RecensMedical, Dutch Opthalmic
    Grant/Research Support: Genentech, Regeneron, Allergan, Clearside, Alimera, Ophthotech, Ophthea, Mylan, Chengdu, Gyroscope, Kodiak, NGM, Alkahest
    Honoraria: Genentech, Regeneron, Allergan, Clearside, Alimera, Notal Vision, EyePoint, Gyroscope, RecensMedical, Dutch Opthalmic
    Speaker's Bureau: Genentech, Allergan, Novartis, EyePoint, Dutch Ophthalmic
    Advisory Board: Genentech, Allergan, Novartis, Kodiak, EyePoint, Adverum
    Stock Shareholder: US Retina, Hemera Biosciences, Network Eye, Clearside

     Rishi P. Singh, MD

    Consultant/Independent Contractor: Regeneron, Alcon, Novartis, Genentech, Bausch and Lomb, Apellis
    Grant/Research Support: Aerie, Graybug, Apellis

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Yaremi Koopot, and Alana Ochoa all have reported that they do not have any relevant financial relationships to disclose.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and iVista Medical Education, Inc. do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/23/20